Amarin Corp Plcuk (AMRN) Short-term Investments (2020 - 2026)
Amarin Corp Plcuk (AMRN) reported Short-term Investments of $176.8 million for Q1 2026, up 8.96% year-over-year from $162.3 million in Q1 2025, and up 5.28% quarter-over-quarter from $167.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Short-term Investments (2020 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 7 years of Short-term Investments data on file, last reported at $176.8 million in Q1 2026.
- Short-term Investments for Q1 2026 came in at $176.8 million, up 8.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $176.8 million (up 8.96% YoY), and the FY2025 annual result was $167.9 million, down 3.03% from the prior year.
- Short-term Investments grew to $176.8 million in Q1 2026 per AMRN's latest filing, from $167.9 million in the prior quarter.
- Over five years, Short-term Investments peaked at $176.8 million in Q1 2026 and troughed at $49.8 million in Q3 2023.
- A 5-year average of $122.1 million and a median of $121.4 million in 2023 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2022 and 2024: Short-term Investments tumbled 75.34% in 2022, then soared 198.48% in 2024.
- A 5-year view of Short-term Investments shows it stood at $91.7 million in 2022, then surged by 32.4% to $121.4 million in 2023, then surged by 42.65% to $173.2 million in 2024, then decreased by 3.03% to $167.9 million in 2025, then climbed by 5.28% to $176.8 million in 2026.
- Business Quant data shows AMRN's Short-term Investments at $176.8 million in Q1 2026, $167.9 million in Q4 2025, and $163.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.80 Mn |
| Dec 31, 2025 | 167.93 Mn |
| Sep 30, 2025 | 163.80 Mn |
| Jun 30, 2025 | 150.80 Mn |
| Mar 31, 2025 | 162.26 Mn |
| Dec 31, 2024 | 173.18 Mn |
| Sep 30, 2024 | 148.79 Mn |
| Jun 30, 2024 | 90.70 Mn |
| Mar 31, 2024 | 94.24 Mn |
| Dec 31, 2023 | 121.41 Mn |
| Sep 30, 2023 | 49.85 Mn |
| Jun 30, 2023 | 79.90 Mn |
| Mar 31, 2023 | 112.96 Mn |
| Dec 31, 2022 | 91.70 Mn |
| Sep 30, 2022 | 63.20 Mn |
| Jun 30, 2022 | 85.23 Mn |
| Mar 31, 2022 | 143.41 Mn |
| Dec 31, 2021 | 234.67 Mn |
| Sep 30, 2021 | 256.30 Mn |
| Jun 30, 2021 | 181.91 Mn |